儿童急性髓系白血病首次异基因造血干细胞移植后复发结局:I-BFM 333例回顾分析
该回顾性I-BFM分析纳入333例首次异基因造血干细胞移植后复发的儿童急性髓系白血病患者。4年总生存概率为14%;
要点
- 首次异基因移植后复发儿童AML的4年总生存概率仅14%。
核心结论
- 儿童AML首次异基因造血干细胞移植后复发者总体生存极差,4年总生存概率为14%。
研究设计与样本
- 回顾性I-BFM分析,纳入333例首次异基因造血干细胞移植后复发的儿童急性髓系白血病患者。
主要发现
- 整体4年总生存概率为14%。
- 接受第二次移植的患者中,获得与未获得后续缓解者生存相当。
临床怎么用
- 对于首次异基因移植后复发的儿童AML,应评估是否可行第二次造血干细胞移植以改善生存。
- 移植物来源和供者选择可能与复发后生存相关,临床决策时可纳入考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outcome of 333 children with acute myeloid leukaemia relapsing after a first allogeneic haematopoietic stem cell transplantation was analyzed. Four-year probability of overall survival (4y-pOS) was 14%. 4y-pOS for 122 children receiving a second haematopoietic stem cell transplantation was 31% and 3% for those that did not (P = <0·0001). Achievement of a subsequent remission impacted survival (P = <0·0001). For patients receiving a second transplant survival with or without achieving a subsequent remission was comparable. Graft source (bone marrow vs. peripheral blood stem cells, P = 0·046) and donor choice (matched family vs. matched unrelated donor, P = 0·029) positively impacted survival after relapse. Disease recurrence and non-relapse mortality at four years reached 45% and 22%.
引用
- Uden T, Bertaina A, Abrahamsson J, et al. Outcome of children relapsing after first allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: a retrospective I-BFM analysis of 333 children. Br J Haematol. 2020. PMID: 32012224. doi:10.1111/bjh.16441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。